Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Sales (2019 - 2025)

Cyclerion Therapeutics has reported Return on Sales over the past 6 years, most recently at 1.15% for Q3 2025.

  • Quarterly results put Return on Sales at 1.15% for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was 1.45% (changed N/A YoY), and the annual figure for FY2022 was 86.98%, down 7297.0%.
  • Return on Sales for Q3 2025 was 1.15% at Cyclerion Therapeutics, up from 17.98% in the prior quarter.
  • Over the last five years, Return on Sales for CYCN hit a ceiling of 1.15% in Q3 2025 and a floor of 216.05% in Q1 2021.
  • Median Return on Sales over the past 4 years was 28.56% (2021), compared with a mean of 44.22%.
  • Biggest five-year swings in Return on Sales: plummeted -19610bps in 2021 and later soared 19779bps in 2022.
  • Cyclerion Therapeutics' Return on Sales stood at 26.9% in 2021, then dropped by -29bps to 34.81% in 2022, then crashed by -146bps to 85.56% in 2023, then soared by 99bps to 1.15% in 2025.
  • The last three reported values for Return on Sales were 1.15% (Q3 2025), 17.98% (Q2 2025), and 17.99% (Q1 2025) per Business Quant data.